FP1 Stock Overview
A clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Salarius Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.41 |
52 Week High | US$1.59 |
52 Week Low | US$0.38 |
Beta | 0.98 |
1 Month Change | -4.69% |
3 Month Change | -24.11% |
1 Year Change | -66.72% |
3 Year Change | -98.42% |
5 Year Change | n/a |
Change since IPO | -99.87% |
Recent News & Updates
Recent updates
Shareholder Returns
FP1 | DE Biotechs | DE Market | |
---|---|---|---|
7D | -3.3% | 1.7% | -0.2% |
1Y | -66.7% | -24.9% | 5.4% |
Return vs Industry: FP1 underperformed the German Biotechs industry which returned -36.2% over the past year.
Return vs Market: FP1 underperformed the German Market which returned 9.1% over the past year.
Price Volatility
FP1 volatility | |
---|---|
FP1 Average Weekly Movement | 23.4% |
Biotechs Industry Average Movement | 5.2% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.5% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: FP1's share price has been volatile over the past 3 months.
Volatility Over Time: FP1's weekly volatility has increased from 16% to 23% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 2 | David Arthur | www.salariuspharma.com |
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors.
Salarius Pharmaceuticals, Inc. Fundamentals Summary
FP1 fundamental statistics | |
---|---|
Market cap | €2.13m |
Earnings (TTM) | -€8.21m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs FP1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FP1 income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$8.92m |
Earnings | -US$8.92m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.87 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 3.2% |
How did FP1 perform over the long term?
See historical performance and comparison